Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Retained Earnings (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Retained Earnings readings, the most recent being -$416.9 million for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 20.72% to -$416.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$416.9 million, a 20.72% decrease, with the full-year FY2025 number at -$339000.0, up 99.9% from a year prior.
  • Retained Earnings hit -$416.9 million in Q4 2025 for Enanta Pharmaceuticals, down from -$339000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $97.2 million in Q1 2021 to a low of -$416.9 million in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$2.7 million (2022), compared with a mean of -$94.6 million.
  • Biggest five-year swings in Retained Earnings: surged 15886.68% in 2021 and later plummeted 64568.54% in 2024.
  • Enanta Pharmaceuticals' Retained Earnings stood at $18.5 million in 2021, then plummeted by 653.41% to -$102.2 million in 2022, then skyrocketed by 99.48% to -$534000.0 in 2023, then plummeted by 64568.54% to -$345.3 million in 2024, then decreased by 20.72% to -$416.9 million in 2025.
  • The last three reported values for Retained Earnings were -$416.9 million (Q4 2025), -$339000.0 (Q3 2025), and -$386.2 million (Q2 2025) per Business Quant data.